Nature Communications (Feb 2017)
CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor
- Tyler Funnell,
- Shinya Tasaki,
- Arusha Oloumi,
- Shinsuke Araki,
- Esther Kong,
- Damian Yap,
- Yusuke Nakayama,
- Christopher S. Hughes,
- S.-W. Grace Cheng,
- Hirokazu Tozaki,
- Misa Iwatani,
- Satoshi Sasaki,
- Tomohiro Ohashi,
- Tohru Miyazaki,
- Nao Morishita,
- Daisuke Morishita,
- Mari Ogasawara-Shimizu,
- Momoko Ohori,
- Shoichi Nakao,
- Masatoshi Karashima,
- Masaya Sano,
- Aiko Murai,
- Toshiyuki Nomura,
- Noriko Uchiyama,
- Tomohiro Kawamoto,
- Ryujiro Hara,
- Osamu Nakanishi,
- Karey Shumansky,
- Jamie Rosner,
- Adrian Wan,
- Steven McKinney,
- Gregg B. Morin,
- Atsushi Nakanishi,
- Sohrab Shah,
- Hiroyoshi Toyoshiba,
- Samuel Aparicio
Affiliations
- Tyler Funnell
- Department of Molecular Oncology, BC Cancer Agency
- Shinya Tasaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Arusha Oloumi
- Department of Molecular Oncology, BC Cancer Agency
- Shinsuke Araki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Esther Kong
- Department of Molecular Oncology, BC Cancer Agency
- Damian Yap
- Department of Molecular Oncology, BC Cancer Agency
- Yusuke Nakayama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Christopher S. Hughes
- Michael Smith Genome Sciences Centre, BC Cancer Agency
- S.-W. Grace Cheng
- Michael Smith Genome Sciences Centre, BC Cancer Agency
- Hirokazu Tozaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Misa Iwatani
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Satoshi Sasaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Tomohiro Ohashi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Tohru Miyazaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Nao Morishita
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Daisuke Morishita
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Mari Ogasawara-Shimizu
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Momoko Ohori
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Shoichi Nakao
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Masatoshi Karashima
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Masaya Sano
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Aiko Murai
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Toshiyuki Nomura
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Noriko Uchiyama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Tomohiro Kawamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Ryujiro Hara
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Osamu Nakanishi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Karey Shumansky
- Department of Molecular Oncology, BC Cancer Agency
- Jamie Rosner
- Department of Molecular Oncology, BC Cancer Agency
- Adrian Wan
- Department of Molecular Oncology, BC Cancer Agency
- Steven McKinney
- Department of Molecular Oncology, BC Cancer Agency
- Gregg B. Morin
- Michael Smith Genome Sciences Centre, BC Cancer Agency
- Atsushi Nakanishi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Sohrab Shah
- Department of Molecular Oncology, BC Cancer Agency
- Hiroyoshi Toyoshiba
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
- Samuel Aparicio
- Department of Molecular Oncology, BC Cancer Agency
- DOI
- https://doi.org/10.1038/s41467-016-0008-7
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 16
Abstract
The phosphorylation of serine/arginine-rich proteins by CDC-like kinase is a central regulatory mechanism for RNA splicing reactions. Here, the authors synthesize a novel small molecule CLK inhibitor and map CLK-responsive alternative splicing events and discover an effect on conjoined gene transcription.